Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
2019 · New England Journal of Medicine · 1,506 citations
https://doi.org/10.1056/nejmoa1903076
T
Toby M. Maher
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
986
Papers
33.9K
Citations
94
h-index
312
i10-index
Toby M. Maher is an academic researcher from University of Southern California. The author has contributed to research in topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis & Systemic Sclerosis and Related Diseases & Sarcoidosis and Beryllium Toxicity Research. The author has an h-index of 94, co-authored 839 publications.
ORCID: 0000-0001-7192-9149Papers by this author
worksAcute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
2016 · American Journal of Respiratory and Critical Care Medicine · 1,408 citations
https://doi.org/10.1164/rccm.201604-0801ci
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
2020 · Pharmacology & Therapeutics · 612 citations
https://doi.org/10.1016/j.pharmthera.2020.107798
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
2019 · The Lancet Respiratory Medicine · 606 citations
https://doi.org/10.1016/s2213-2600(19)30341-8
Interstitial lung diseases
2022 · The Lancet · 454 citations
https://doi.org/10.1016/s0140-6736(22)01052-2
PD-1 up-regulation on CD4 <sup>+</sup> T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
2018 · Science Translational Medicine · 355 citations
https://doi.org/10.1126/scitranslmed.aar8356
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat